These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 32827269)

  • 1. Increase in endogenous glucose production with SGLT2 inhibition is attenuated in individuals who underwent kidney transplantation and bilateral native nephrectomy.
    Daniele G; Solis-Herrera C; Dardano A; Mari A; Tura A; Giusti L; Kurumthodathu JJ; Campi B; Saba A; Bianchi AM; Tregnaghi C; Egidi MF; Abdul-Ghani M; DeFronzo R; Del Prato S
    Diabetologia; 2020 Nov; 63(11):2423-2433. PubMed ID: 32827269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increase in Endogenous Glucose Production With SGLT2 Inhibition Is Unchanged by Renal Denervation and Correlates Strongly With the Increase in Urinary Glucose Excretion.
    Solis-Herrera C; Daniele G; Alatrach M; Agyin C; Triplitt C; Adams J; Patel R; Gastaldelli A; Honka H; Chen X; Abdul-Ghani M; Cersosimo E; Del Prato S; DeFronzo R
    Diabetes Care; 2020 May; 43(5):1065-1069. PubMed ID: 32144165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of the sodium-glucose cotransporter 2 inhibitor dapagliflozin on substrate metabolism in prediabetic insulin resistant individuals: A randomized, double-blind crossover trial.
    Veelen A; Andriessen C; Op den Kamp Y; Erazo-Tapia E; de Ligt M; Mevenkamp J; Jörgensen JA; Moonen-Kornips E; Schaart G; Esterline R; Havekes B; Oscarsson J; Schrauwen-Hinderling VB; Phielix E; Schrauwen P
    Metabolism; 2023 Mar; 140():155396. PubMed ID: 36592688
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors.
    Alatrach M; Laichuthai N; Martinez R; Agyin C; Ali AM; Al-Jobori H; Lavynenko O; Adams J; Triplitt C; DeFronzo R; Cersosimo E; Abdul-Ghani M
    Diabetes; 2020 Apr; 69(4):681-688. PubMed ID: 31915153
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gluconeogenesis, But Not Glycogenolysis, Contributes to the Increase in Endogenous Glucose Production by SGLT-2 Inhibition.
    Wolf P; Fellinger P; Pfleger L; Beiglböck H; Krumpolec P; Barbieri C; Gastaldelli A; Harreiter J; Metz M; Scherer T; Zeyda M; Baumgartner-Parzer S; Marculescu R; Trattnig S; Kautzky-Willer A; Krššák M; Krebs M
    Diabetes Care; 2021 Feb; 44(2):541-548. PubMed ID: 33318126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
    Merovci A; Solis-Herrera C; Daniele G; Eldor R; Fiorentino TV; Tripathy D; Xiong J; Perez Z; Norton L; Abdul-Ghani MA; DeFronzo RA
    J Clin Invest; 2014 Feb; 124(2):509-14. PubMed ID: 24463448
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Parameters, Fuel Oxidation, and Glucose Kinetics in Patients With Type 2 Diabetes Treated With Dapagliflozin Plus Saxagliptin.
    Qin Y; Adams J; Solis-Herrera C; Triplitt C; DeFronzo R; Cersosimo E
    Diabetes Care; 2020 Oct; 43(10):2519-2527. PubMed ID: 32694214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of the SGLT2 Inhibitor Dapagliflozin on Energy Metabolism in Patients With Type 2 Diabetes: A Randomized, Double-Blind Crossover Trial.
    Op den Kamp YJM; de Ligt M; Dautzenberg B; Kornips E; Esterline R; Hesselink MKC; Hoeks J; Schrauwen-Hinderling VB; Havekes B; Oscarsson J; Phielix E; Schrauwen P
    Diabetes Care; 2021 Jun; 44(6):1334-1343. PubMed ID: 33858855
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin and glucose-lowering agents for treating people with diabetes and chronic kidney disease.
    Lo C; Toyama T; Wang Y; Lin J; Hirakawa Y; Jun M; Cass A; Hawley CM; Pilmore H; Badve SV; Perkovic V; Zoungas S
    Cochrane Database Syst Rev; 2018 Sep; 9(9):CD011798. PubMed ID: 30246878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
    Ferrannini E; Muscelli E; Frascerra S; Baldi S; Mari A; Heise T; Broedl UC; Woerle HJ
    J Clin Invest; 2014 Feb; 124(2):499-508. PubMed ID: 24463454
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride].
    Strojek K; Yoon KH; Hruba V; Elze M; Langkilde AM; Parikh S
    Dtsch Med Wochenschr; 2013 Apr; 138 Suppl 1():S16-26. PubMed ID: 23529567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin as monotherapy in drug-naive Asian patients with type 2 diabetes mellitus: a randomized, blinded, prospective phase III study.
    Ji L; Ma J; Li H; Mansfield TA; T'joen CL; Iqbal N; Ptaszynska A; List JF
    Clin Ther; 2014 Jan; 36(1):84-100.e9. PubMed ID: 24378206
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.